Savant HWP Announces NIDA Funding for Pre-Clinical Development of 18-MC as Potential Treatment for Addiction, Obesity

Published January 7, 2013

Savant HWP Announces NIDA Funding For Pre-Clinical Development Of 18-MC As Potential Treatment For Addiction, Obesity
Filed under: Drug Abuse and Addiction
Savant HWP, Inc. today announced the receipt of a three-year grant to support the development of 18-MC (18-methoxycoronaridine) as a potential orally active treatment for drug addiction, obesity and other forms of compulsive behavior.
Source

Find More Drug Abuse And Addiction Information…